Sanofi and Sobi's hemophilia drug meets phase III primary endpoint

A phase III study conducted by pharmaceutical firms Sanofi and Sobi investigating potential hemophilia A treatment efanesoctocog has met its primary endpoint.

Photo: John Ambrose / Sobi / PR

Sanofi and Swedish Orphan Biovitrum, commonly known as Sobi, have presented positive top line results from a phase III trial with efanesoctocog, a hemophilia A treatment candidate, as reported in a press release on Wednesday.

The trial tested the safety, efficacy and pharmacokinetics of efanesoctocog alfa (BIVV001) in severe hemophilia A patients who were older than 12 and had previously received treatment.

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

Further reading

Related articles

Latest news

See all jobs